MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
London, United Kingdom, 6th December 2022 / Sciad Newswire / MultiOmic Health, an artificial intelligence-enabled precision medicine discovery company, today announces the signing of a research collaboration agreement with Northern Care Alliance (NCA) NHS Foundation Trust in Manchester, England. MultiOmic will deploy its MOHSAIC® platform on de-identified bio-samples and clinical histories previously collected by NCA to investigate patient stratifying biomarkers in diabetic nephropathy using integrative multi-omics analyses.
“This collaboration involves our Salford Kidney Study (one of the largest chronic kidney disease cohorts in the world) with a specific focus on a diabetic sub-cohort,” said Professor Philip Kalra, Director of Research & Innovation at NCA and a leading kidney specialist in UK clinical research and nephrologist education. “I am particularly excited by the use of multiple omics modalities in the analysis which could lead to new insights that greatly improve patient prognosis. This is a major step on the way towards personalised medicine in a very common but serious condition.”
“Diabetic nephropathy is a chronic multi-factorial disease driven by a complex interplay between inherited factors and the cumulative effect of diet, lifestyle and environmental exposures,” said Slaven Stekovic, Chief Scientific Officer at MultiOmic.
“Traditional genome-wide association studies (GWAS) looking only at the genome have been unable to explain the disease progression of the vast majority of chronic kidney disease patients,” said Ariella Cohain, Chief Technology Officer at MultiOmic. “By integrating the genome, epigenome, proteome and metabolome, we aim to gain a deeper understanding of all the factors which drive this debilitating disease.”
An estimated 30% to 40% of diabetics eventually develop chronic kidney disease1. Diabetic kidney disease patients now account for an estimated $300 billion per year2 in global healthcare costs. Recently published research indicates that the risk of developing type 2 diabetes3 or incurring kidney damage4 in later life is increased in COVID-19 survivors, leading to an expected acceleration in disease prevalence over the next two decades.
For avoidance of doubt, all patient information provided to MultiOmic by its research collaborators is de-identified, fully consented and in compliance with relevant privacy and data protection legislation, regulations and guidance, including but not limited to the General Data Protection Regulation (GDPR) in both the European Union and the United Kingdom.
For further information, please contact:
Sciad Communications, Media Relations
Richard Anderson / Sophie Protheroe
Notes to Editors
About MultiOmic Health
MultiOmic Health is an AI-enabled drug discovery (AIDD) company dedicated to chronic multi-factorial diseases, with an initial focus on the metabolic syndrome-related conditions. It partners with research institutions, healthcare providers and healthtech companies to source de-identified patient data and bio-samples. Drawing upon these carefully selected data sources, MultiOmic’s MOHSAIC® platform combines integrated multi-omics analysis and computational systems biology modeling with targeted wet laboratory experiments to originate novel precision therapeutic concepts. MultiOmic subsequently partners with established biopharma companies to take its therapeutic concepts into global clinical trial programs and market the ensuing medicines. Its experienced leadership team blends commercial, technical and operational expertise from across the pharma, systems biology and AI/big data arenas.
About Northern Care Alliance
Northern Care Alliance NHS Foundation Trust was established on 1 October 2021 bringing together Salford Royal NHS Foundation Trust and The Pennine Acute Hospitals NHS Trust. NCA provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Its dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond.
1. ‘Shared professional practice on kidney care and diabetes’, Diabetes UK.
2. MultiOmic Health estimates based on global forecasts of spending on T2D and CKD for patients with both conditions using data from the WHO, CMS, IDF and CDC.
3. ‘Diabetes risk rises after COVID’, Nature (2022). Article: https://www.nature.com/articles/d41586-022-00912-y
4. ‘Covid-19: Infection increases the risk of kidney disease even in mild cases’, British Medical Journal (2021). Article: https://www.bmj.com/content/374/bmj.n2189
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.